Resubmission After Withdrawal: US FDA’s Mavenclad Approval Acknowledges Long Regulatory History
Executive Summary
EMD Serono’s multiple sclerosis drug joins small cadre of products that survived a refuse to file letter and NDA withdrawal; chart details recent RTFs and application withdrawals.